Jonathan Zalevsky Nektar Therapeutics (NKTR) insider trading activity

NKTR Quotes by TradingView

Jonathan Zalevsky is Chief R&D Officer of NEKTAR THERAPEUTICS. Currently has a direct ownership of 257,670 shares of NKTR, which is worth approximately $319,510. The most recent transaction as insider was on May 17, 2024, when has been sold 7,355 shares (Common Stock) at a price of $1.75 per share, resulting in proceeds of $12,871. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 258K
2.78% 3M change
12.17% 12M change
Total Value Held $319,510

Jonathan Zalevsky Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 17 2024
SELL
Open market or private sale
$12,871 $1.75 p/Share
7,355 Reduced 2.78%
257,670 Common Stock
Feb 20 2024
SELL
Open market or private sale
$6,129 $0.68 p/Share
9,014 Reduced 3.29%
265,025 Common Stock
Nov 17 2023
SELL
Open market or private sale
$4,726 $0.49 p/Share
9,646 Reduced 3.4%
274,039 Common Stock
Aug 16 2023
SELL
Open market or private sale
$7,568 $0.78 p/Share
9,703 Reduced 3.31%
283,685 Common Stock
May 16 2023
SELL
Open market or private sale
$7,049 $0.72 p/Share
9,791 Reduced 3.23%
293,388 Common Stock
Feb 16 2023
SELL
Open market or private sale
$31,452 $3.0 p/Share
10,484 Reduced 3.34%
303,179 Common Stock
Nov 16 2022
SELL
Open market or private sale
$48,052 $3.57 p/Share
13,460 Reduced 4.11%
313,663 Common Stock
Aug 18 2022
SELL
Open market or private sale
$342,779 $4.65 p/Share
73,716 Reduced 18.39%
327,123 Common Stock
Aug 16 2022
SELL
Open market or private sale
$50,266 $4.76 p/Share
10,560 Reduced 2.57%
400,839 Common Stock
Aug 15 2022
BUY
Grant, award, or other acquisition
-
135,000 Added 24.71%
411,399 Common Stock
May 16 2022
SELL
Open market or private sale
$85,608 $3.95 p/Share
21,673 Reduced 7.27%
276,399 Common Stock
May 15 2022
BUY
Grant, award, or other acquisition
-
23,950 Added 7.44%
298,072 Common Stock
Feb 16 2022
SELL
Open market or private sale
$119,486 $10.95 p/Share
10,912 Reduced 3.83%
274,122 Common Stock
Dec 16 2021
BUY
Grant, award, or other acquisition
-
52,950 Added 15.67%
285,034 Common Stock
Nov 16 2021
SELL
Open market or private sale
$274,636 $13.16 p/Share
20,869 Reduced 8.25%
232,084 Common Stock
Nov 15 2021
BUY
Grant, award, or other acquisition
-
40,150 Added 13.7%
252,953 Common Stock
Aug 16 2021
SELL
Open market or private sale
$105,965 $13.83 p/Share
7,662 Reduced 3.48%
212,803 Common Stock
May 17 2021
SELL
Open market or private sale
$569,331 $18.3 p/Share
31,111 Reduced 11.69%
235,065 Common Stock
Feb 16 2021
SELL
Open market or private sale
$540,034 $22.37 p/Share
24,141 Reduced 8.32%
266,176 Common Stock
Dec 18 2020
BUY
Grant, award, or other acquisition
-
40,000 Added 12.11%
290,317 Common Stock
Nov 23 2020
SELL
Open market or private sale
$268,632 $16.4 p/Share
16,380 Reduced 6.14%
250,317 Common Stock
Nov 16 2020
SELL
Open market or private sale
$501,433 $16.93 p/Share
29,618 Reduced 10.0%
266,697 Common Stock
JZ

Jonathan Zalevsky

Chief R&D Officer
San Francisco, CA

Track Institutional and Insider Activities on NKTR

Follow NEKTAR THERAPEUTICS and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NKTR shares.

Notify only if

Insider Trading

Get notified when an Nektar Therapeutics insider buys or sells NKTR shares.

Notify only if

News

Receive news related to NEKTAR THERAPEUTICS

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NKTR